Health Catalyst (NASDAQ:HCAT) General Counsel Benjamin Landry Sells 29,478 Shares of Company Stock

Health Catalyst, Inc. (NASDAQ:HCAT – Get Free Report) General Counsel Benjamin Landry sold 29,478 shares of Health Catalyst stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $1.39, for a total transaction of $40,974.42. Following the completion of the sale, the general counsel owned 251,894 shares of the company’s stock, valued at approximately $350,132.66. This trade represents a 10.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Benjamin Landry also recently made the following trade(s):

  • On Wednesday, November 11th, Benjamin Landry sold 70,000 shares of Health Catalyst stock. The shares were sold at an average price of $1.43, for a total transaction of $100,100.00.

Health Catalyst Price Performance

HCAT traded up $0.15 during trading on Friday, hitting $1.51. The company had a trading volume of 465,291 shares, compared to its average volume of 348,183. Health Catalyst, Inc. has a 1-year low of $0.96 and a 1-year high of $3.02. The company has a market cap of $114.99 million, a PE ratio of -0.53 and a beta of 1.52. The business has a 50-day moving average of $1.69 and a 200-day moving average of $1.68.

Health Catalyst (NASDAQ:HCAT – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.02. The company had revenue of $56.28 million during the quarter, compared to analyst estimates of $55.39 million. Health Catalyst had a negative net margin of 74.24% and a negative return on equity of 4.84%. Research analysts forecast that Health Catalyst, Inc. will post -0.18 earnings per share for the current year.

Institutional Investors Weigh In On Health Catalyst

Institutional investors and hedge funds have recently made changes to their positions in the company. Palogic Value Management L.P. bought a new position in Health Catalyst during the second quarter worth $9,796,000. BlackRock Inc. acquired a new position in Health Catalyst in the second quarter worth $3,654,000. Marshall Wace LLP acquired a new position in Health Catalyst in the third quarter worth $1,810,000. Hsbc Holdings PLC acquired a new position in Health Catalyst in the second quarter worth $809,000. Finally, Squarepoint Ops LLC increased its stake in Health Catalyst by 1,214.8% during the second quarter. Squarepoint Ops LLC now owns 400,210 shares of the company’s stock valued at $796,000 after purchasing an additional 369,772 shares during the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on HCAT shares. Wells Fargo & Company cut their target price on shares of Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating on the stock in a research note on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Health Catalyst in a research note on Monday, October 26th. Canaccord Genuity Group lowered Health Catalyst from a “buy” rating to a “hold” rating and lowered their price objective for the company from $3.00 to $1.80 in a report on Thursday, August 20th. Finally, Citigroup lowered their price objective on Health Catalyst from $2.50 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Five investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $2.01.

View Our Latest Report on HCAT

About Health Catalyst

(Get Free Report)

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions are designed to help providers use clinical, operational, and financial data to support decision-making and improve care delivery. The company’s offerings include a data platform that brings together information from multiple sources, analytics applications for healthcare workflows, and professional services. These services can include implementation, data management, and support for organizations developing and applying analytics programs.

See Also

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.